Evidence map›Paper›PMID 39556028›Full record

ArticleJournal of comparative effectiveness research2024

Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis.

Alexandrina Balanean, Cherrishe Brown-Bickerstaff, Andrew Klink, Vardhaman Patel, Hanke Zheng, Laetitia N'Dri, Keith Wittstock, Bruce Feinberg, Mark Chaballa, Vadim Khaychuk and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of comparative effectiveness research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Rheumatoid Arthritis Therapy Based on B Cells.Drug design, development and therapy · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alexandrina BalaneanCardinal Health, Dublin, OH 43017, USA.
Cherrishe Brown-BickerstaffCardinal Health, Dublin, OH 43017, USA.
Andrew KlinkCardinal Health, Dublin, OH 43017, USA.ORCID 0000-0003-3765-0448
Vardhaman PatelBristol Myers Squibb, Princeton, NJ 08540, USA.ORCID 0000-0002-3636-3423
Hanke ZhengBristol Myers Squibb, Princeton, NJ 08540, USA.ORCID 0000-0002-4992-121X
Laetitia N'DriBristol Myers Squibb, Princeton, NJ 08540, USA.
Keith WittstockBristol Myers Squibb, Princeton, NJ 08540, USA.ORCID 0000-0002-4080-1916
Bruce FeinbergCardinal Health, Dublin, OH 43017, USA.ORCID 0000-0001-9267-9994
Mark ChaballaBristol Myers Squibb, Princeton, NJ 08540, USA.
Vadim KhaychukBristol Myers Squibb, Princeton, NJ 08540, USA.
Jill KaufmanCardinal Health, Dublin, OH 43017, USA.
Prathamesh PathakCardinal Health, Dublin, OH 43017, USA.
Gordon LamArthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC 28207, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AbataceptAnti-Citrullinated Protein AntibodiesAntirheumatic AgentsArthritis, RheumatoidRheumatoid FactorAdultAgedFemaleHumansMaleMethotrexateMiddle AgedRetrospective StudiesSeverity of Illness IndexTreatment OutcomeAbataceptAnti-Citrullinated Protein AntibodiesAntirheumatic AgentsMethotrexateRheumatoid Factorabataceptanticitrullinated protein antibodyfirst-line therapyrheumatoid arthritisrheumatoid factor

Identifiers

PMID39556028
PMCPMC11609992

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.